Zacks Small-Cap Research

scr.zacks.com

December 19, 2011
Jason Napodano, CFA
312-265-9421
jnapodano@zacks.com

111 North Canal Street, Chicago, IL 60606

Trius Therapeutics (TSRX-NASDAQ)

TSRX: 1st Phase 3 Trial With Tedizolid Meets Primary & Secondary Endpoints…

Current Recommendation	**Outperform**
Prior Recommendation	N/A
Date of Last Change	01/24/2011
Current Price (12/19/11)	$6.21
Target Price	**$11.00**

UPDATE

On December 19, 2011, Trius Therapeutics announced results from the company's 1st phase 3 trial (Study-112) studying 200mg once-daily oral tedizolid (TZD) for 6 days versus 600mg twice-daily oral linezolid (Pfizer's Zyvox) for 10 days in patients with acute bacterial skin and skin structure infections (ABSSSI).

We are maintaining our 'Outperform' rating and adjusting our target to $10 price target on Trius Therapeutics. We believe the company's phase 3 candidate, Tedizolid, is now one of the lowest-risk phase 3 assets in biotech. A marketing partnership for Europe in 2012 is the biggest catalyst for the shares in the near future.

SUMMARY DATA

52-Week High	**$8.74**
52-Week Low	**$3.25**
One-Year Return (%)	**110.15**
Beta	**0.15**
Average Daily Volume (sh)	**119,289**
Shares Outstanding (mil)	**29**
Market Capitalization ($mil)	**$195**
Short Interest Ratio (days)	**3.85**
Institutional Ownership (%)	**21**
Insider Ownership (%)	**61**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using 2011 Estimate	**N/A**
P/E using 2012 Estimate	**N/A**

Risk Level	**Above Average**
Type of Stock	**Small-Growth**
Industry	**Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue
(In millions of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2010	1.5 A	2.1 A	1.9 A	2.5 A	8.0 A
2011	2.7 A	2.9 A	30.4 A	5.5 E	41.5 E
2012					25.0 E
2013					25.0 E

Earnings per Share
(EPS is operating earnings before non-recurring items)


	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2010	-$5.08 A	-$2.69 A	-$0.57 A	-$0.37 A	-$2.36 A
2011	-$0.43 A	-$0.40 A	$0.49 E	-$0.37 E	-$0.62 E
2012					-$0.90 E
2013					-$0.61 E

© Copyright 2011, Zacks Investment Research. All Rights Reserved.

WHAT'S NEW

1st Phase 3 Trial Meets Primary & Secondary Endpoints

On December 19, 2011, Trius Therapeutics announced results from the company's 1st phase 3 trial (Study-112) studying 200mg once-daily oral tedizolid (TZD) for 6 days versus 600mg twice-daily oral linezolid (Pfizer's Zyvox) for 10 days in patients with acute bacterial skin and skin structure infections (ABSSSI).



The trial was a non-inferiority design (90% power to detect a 10% non-inferiority margin between the two arms). The trial enrolled a total of 667 patients across sites in North America.

The primary endpoint was cessation of lesion spread and resolution of fever at 48-72 hours after initiation of study drug on an intent-to-treat (ITT) analysis. There were also key secondary endpoints, including sustained clinical response at end-of-treatment (EOT) in the ITT and clinically evaluable (CE) populations and an investigator's assessment of clinical success in the ITT and CE populations.

…Top-Line Data…

ABSSSI	Tedizolid	Linezolid
Dosing Regimen	200mg QD For 6 Days	600mg BID For 10 Days
Primary Endpoint		
Cessation of Spread & Absence of Fever at 48-72 hrs	79.5%	79.4%
Secondary Endpoints		
Sustained Response (Day 10) – ITT	69.3%	71.9%
Sustained Response (Day 10) – CE	80.2%	81.1%
Investigator Assessment (Day 7-14) – ITT	85.5%	86.0%
Investigator Assessment (Day 7-14) – CE	94.6%	95.4%
>20% Decrease in Lesion Area (48-72 hrs)	78.0%	76.1%
Safety & Tolerability		
Treatment Emergent Adverse Event (TEAE)	40.8%	43.3%
Any Drug Related TEAE	24.2%	31.0%
Gastrointestinal Disorders	16.3%	24.4%

…Quick Analysis…

The data above look very good. As noted in our previous report (December 6, 2011), management did not expect tedizolid to achieve superiority to linezolid. To achieve superiority, tedizolid drug would have had to have posted a primary endpoint >7% versus linezolid. Truth be told, linezolid is a highly effective drug. Pfizer would not have sold $1.2 billion of Zyvox in 2010 if the drug didn't work. We note the rates of methicillin-resistance *Staphylococcus aureus* (MRSA) infection and outcomes were similar between both arms.

We are surprised that the primary outcome was so close, but we note that the primary endpoint is a composite of both cessation of lesions and absence in fever. According to management, tedizolid offers up numerically better results on the cessation of lesions endpoint – approximately 87% vs. 85%. Both drugs lost efficacy points due to missing temperature data. It becomes difficult to prove in a clinical setting the rapid onset of efficacy when clinicians are not always following the exact FDA guidelines with respect for registration of a new drug application. We think these data are consistent with the clinical profile of the drug demonstrated in early trials.

That being said, what did show a positive trend in the favor for tedizolid was the tolerability. Treatment emergent adverse events were higher for linezolid. Gastrointestinal disorders, which include nausea, vomiting, and diarrhea, were statistically significant in favor of tedizolid. Besides better tolerability, we noted the significant administrative and convenience advantages of tedizolid versus linezolid, including a shorter course of treatment (6 days vs. 10 days), once-daily dosing, and bioequivalence between the oral and IV dose. We think the drug can gain market share from linezolid based on these advantages.

However, superiority was the "home run" in our view. With the above marketing advantages on safety and convenience and a superior efficacy claim, we think tedizolid could have best-in-class. Based on the top-line data from Study-112, we still think tedizolid will be a very nice drug for Trius. Paramount is that Trius gets the drug on the market before Zyvox loses patent exclusivity in mid-2015.

…Second Phase 3 Ongoing…

We remind investors that Trius is also testing tedizolid is second phase 3 trial, Study-113, also under a U.S. FDA SPA. Stuyd-113 is an IV-to-Oral step-down trial that will compare the efficacy and safety of 200mg QD tedizolid for 6 days to 600mg BID linezolid (Zyvox) for 10 days. All patients will be initiated on IV dosage form for a minimum of one day and be transitioned to the oral dose form at the discretion of the clinical investigator. We note that having both an IV and oral dosage formulation is a key differentiator to Cubist's Cubicin (daptomycin). We expect data from this program either late 2012 or in early 2013.

INVESTMENT OVERVIEW

Analyst R&D Day Highlights Potential of Tedizolid

On December 1, 2011, Trius Therapeutics hosted an Analyst / R&D day to highlight the potential of tedizolid phosphate (TZD), the company's second generation oxazolidinone for the treatment of serious gram-positive infections, including methicillin-resistance *Staphylococcus aureus* (MRSA). The event started out with CEO, Jeff Stein, discussing the company's development progress to date with TZD. Mr. Stein highlighted the impressive clinical and non-clinical data generated with the drug. The goal has been to optimize the label for TZD once approved. We highlight some of the key safety and efficacy findings from the clinical and non-clinical programs below:

- Animal model data demonstrated higher and more rapid cure-rates vs. linezolid (Pfizer's Zyvox), including data showing superiority in lung and systemic models of infections.

- Animal model data demonstrated a superior (3 to 9-fold) therapeutic window compared to Linezolid with respect to GLP acute and chronic toxicity studies. The data also show no monamine oxidase (MAO) mediated drug-drug interactions or impact on heart rate or blood pressure in the presence of tyramine. This is a potential advantage for dosing with SSRI's or vasoconstrictors.

- The phase 1 program consisted of 11 studies in 271 subjects. Phase 1 data showed TZD had no myelosuppression or immunosuppression, another key advantage when compare to Linezolid. The data shows TZD offers a far more predictable pharmacokinetic (PK) profile than linezolid, with superior bioavailability and uniform bioequivalence between the oral and IV dose. Earlier in the year, Trius reported data from a phase 1 study showing high concentrations in lung tissue predictive of clinical efficacy.

- Phase 2 data with 200mg once-daily (QD) TZD yielded a 98% cure rate at test-of-cure (TOC), the FDA's old guidelines for approval, and a 91% cure rate under the new ABSSSI early endpoint guidelines. During the phase 2 program, there were no serious drug related adverse events or adverse event related discontinuations.

The data generated with TZD to date has been impressive. Based on clinical data from phase 1 and phase 2 studies, tedizolid offers several key advantages over Zyvox, including rapid bactericidal onset, convenient once-daily dosing, a shorter course of therapy at (6 days vs. 10 to 14 days), and superior cure rates in difficult-to-treat MRSA infections. Plus, the uniform and predictable PK profile and bioequivalence between the oral and IV dose formulations is another key advantage for the drug.

Two phase 3 programs are going for registration in ABSSSI. Trius is in discussions with the U.S. FDA on a third phase 3 program to focus on lung infections. This could be another significant differentiator to Cubist's Cubicin (daptomycin). We expect that management will also seek to conduct a study in bacteremia in 2013, providing yet another strong point of differentiation to Pfizer's Zyvox (linezolid).

…Key Advantages vs. Both Zyvox & Cubicin…

	Zyvox (linezolid)	Cubicin (daptomycin)	Tedizolid
IV & Oral Formulation	YES	NO	YES
Once Daily Dosing	NO	YES	YES
Short Course of Therapy	NO	NO	YES
Skin Infections	YES	YES	YES
Active In Lung Infections	YES	NO	YES
Bacteremia	NO	YES	YES
Superior Tolerability	NO	NO	YES

…Bayer Takes Asia/Pacific Rights…

On July 27, 2011, Trius announced it had formed a strategic collaboration to develop and commercialize Tedizolid in Asia/Pacific and emerging markets (Africa, Middle East, and Latin America) with Bayer Pharma AG. Trius has retained full development and commercialization rights outside the Bayer territory, which includes unencumbered rights in the U.S., Canada, and Europe.

Under terms of the agreement, Bayer paid Trius a $25 million upfront payment and will support approximately 25% of the future development costs of Tedizolid required for global approval in acute bacterial skin and skin structure infections (ABSSSI) and pneumonia. In addition, Trius is eligible to receive up to $69 million in certain development, regulatory, and commercial milestones, along with double digit royalties (we model 15%) on sales. We noted that 50% of these milestones are pre-commercialization. For example, Trius recognized $2.0 million already under the collaboration in the third quarter 2011 for the initiation of the 2nd phase 3 trial, Study-113) with TZD.

We are particularly excited about the deal for a number of reasons:

- ✓ Firstly, Bayer is an outstanding commercial partner, with expertise in anti-infectants including Cipro and Avalox. Bayer has the financial strength and experience to launch Tedizolid in Asia, including China, and potential emerging markets across the Africa and the Middle East. Bayer just recently moved its commercial operations for Asia to China. We expect Bayer to commence clinical work in China / Japan shortly.

- ✓ Secondly, the $25 million upfront payment provides Trius with much needed cash. Trius exited the third quarter 2011 with $69.5 million in cash. Bayer will also reimburse Trius for approximately 25% of global development costs, including 100% in China and Japan. This includes unfinished preclinical and CMC work. Respiratory infections like Avian Flu and SARS are significant medical concern in Asia, and we believe TZD has significant potential to treat lung infections, a key differentiator from Cubists Cubicin, in China and Japan.

- ✓ Thirdly, Trius retains the unencumbered rights to develop, commercialize or separately partner in the U.S., Canada, and the EU. We believe the above deal with Bayer is just a taste of what could come in terms of a U.S. or European deal for TZD following successful completion of the first phase 3 trial. We note the company has reported entering into confidential disclosure agreements (CDAs) with several interested parties.

- ✓ Finally, it validates our belief that TZD is a potential big drug on a global basis, with differentiating factors from both Pifzer's Zyvox (linezolid) and Cubist's Cubicin (daptomycin), and reinforces our assumption that Trius can sign a larger deal for Tedizolid in unlicensed territories in 2012.

…Commercial Potential Is Very Attractive…


We see a significant commercial potential for TZD in the U.S. If the second phase 3 program goes as we expect, the drug has peak sales in the $300 million to $350 million range in North America. The current market is dominated by vancomycin and linezolid. The therapeutic window on both is closing. Key for Trius is to gain the cleanest and widest label possible. Expanding the indications into HAP/VAP, pneumonia, and bacteremia provide meaningful upside to our forecast.

This is clearly a large market. U.S. sales for Zyvox, Cubicin, Tygacil, and generic vancomycin eclipsed $1.5 billion in 2010. Vancomycin prescriptions grew by 6% CAGR between 2005 and 2010. Yet, despite the presence of generic vancomycin, branded sales of Zyvox, Cubicin, and Tygacil grew by 20% CAGR. The market is shifting to more effective drugs, and price is becoming less of a factor.


In fact, initial market research conducted by management on formulary acceptance shows that with a non-inferior profile to Zyvox, TZD will see broad (~90%) Tier-2 coverage at parity pricing per course of treatment (roughly $1,500) to Zyvox. This includes a range of indications, including skin, HAP/VAP, Bacteremia, and MRSA.


The Trius R&D day offers perspective from two leading physicians with significant experience in treating patients with MRSA: Dr. Ralph Corey, Profession or Medicine and Infectious disease at Duke University and Dr. Jeff Kingsley, CEO of the Southeast Regional Research Group. Both doctors concluded that despite the availability of generic vancomycin and expensive branded products such as Zyvox, Cubicin, and Tygacil, a void remained in the market for a highly effective drug that met all the requirements for success.


Based on data presented by management on the clinical and non-clinical history of TZD, we see the drug is poised to be “Best-in-Class” with a full label.



…A Large And Growing Market…







Based on current timelines, we are expecting a new drug application (NDA) around the middle of 2013, with FDA approval in 2014. Additional applications for HAP/VAP, pneumonia, and bacteremia should follow in 2014 and beyond. The biggest near-term catalyst for the shares is a deal for the European market, perhaps in 2012.

…Quick Financial Snap-Shot…

On November 11, 2011, Trius reported financial results for the third quarter 2011. Total revenues in the quarter were $30.4 million, and consisted of the full recognition of the $25 million upfront payment from Bayer Pharma AG for strategic collaboration to develop and commercialize Tedizolid in Asia/Pacific and emerging markets (Africa, Middle East, and Latin America), along with $2.0 million in a milestone earned under the collaboration, and $3.4 million under the company's federal research contract with the Defense Threat Reduction Agency (DTRA).

Income for the quarter totaled $14.3 million, or $0.49 per share. Trius exited the third quarter ended September 30, 2011 with $69.5 million in cash and investments. We forecast that Trius will exit 2011 with roughly $60 million in cash and investments, enough to fund operations through the current phase 3 program.

VALUATION & RECOMMENDATION

Rating Outperform / Target of $10

In January 2011 we initiated coverage of Trius Inc. with an Outperform rating. We are confident in the outcome of the company's ongoing phase 3 program testing tedizolid vs. Pfizer's Zyvox (linezolid) for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The first trial, Study-112, offered positive top-line data in December 2011. This trial was run under a U.S. FDA special protocol assessment (SPA). The second trial, Study-113, also under a U.S. FDA SPA, continues on plan, with data expected late 2012. Management is seeking a third SPA for a lung study in 2012. A study in bacteremia could begin in 2013. All-in-all we are very confident in the development program for tedizolid. We believe it represents one of the lowest risk phase 3 assets in biotech.

We see meaningful market share gains for tedizolid over the three market leading products, Zyvox, Cubicin, and Tygacil. The current market cap of only ~$180 million undervalues the story in our view. We think the stock is worth $10 per share based on discounted cash flow (DCF) analysis. Our U.S. peak sales forecast is $350 million. Our global peak sales forecast is $750 million. We present our DCF Model below.

Trius Therapeutics (TSRX)	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Tedizolid N.A. Sales (Full)	$0	$0	$0	$0	$27.9	$71.6	$134.2	$192.3	$251.4	$288.9	$327.9	$351.7
YoY Growth	-	-	-	-	-	*157%*	*88%*	*43%*	*31%*	*15%*	*14%*	*7%*
Royalty on Ex-N.A. Sales	$0	$0	$0	$0	$3.0	$9.0	$18.9	$31.1	$41.7	$47.8	$53.5	$59.4
YoY Growth	-	-	-	-	-	*203%*	*110%*	*65%*	*34%*	*15%*	*12%*	*11%*
Pipeline	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Grants, Licensing & Collabs	$25.0	$37.5	$5.0	$25.0	$35.0	$0.0	$10.0	$0.0	$15.0	$0.0	$0.0	$0.0
Cash Revenues (in Millions)	$25.0	$37.5	$5.0	$25.0	$65.8	$80.5	$163.1	$223.4	$308.1	$336.8	$381.4	$411.2
CoGS	*$0*	*$0*	*$0*	*$0*	*$2.8*	*$7.2*	*$12.7*	*$17.3*	*$21.4*	*$23.1*	*$26.2*	*$28.1*
R&D	*$49.2*	*$40.0*	*$30.0*	*$25.0*	*$20.0*	*$22.0*	*$24.0*	*$25.0*	*$25.0*	*$25.0*	*$25.0*	*$25.0*
SG&A	*$11.6*	*$12.5*	*$14.0*	*$12.5*	*$25.3*	*$29.7*	*$35.9*	*$41.7*	*$47.6*	*$51.4*	*$55.3*	*$57.7*
Other Expenses	*$0*	*$0*	*$0*	*$0*	*$15.3*	*$6.4*	*$12.7*	*$19.4*	*$25.7*	*$29.5*	*$33.2*	*$36.3*
EBITDA	($35.8)	($15.0)	($39.0)	($12.5)	$2.4	$15.3	$77.7	$120.0	$188.4	$207.8	$241.6	$264.0
Depreciation and amortization	*$0.5*	*$0.5*	*$0.5*	*$0.5*	*$0.5*	*$0.5*	*$0.5*	*$1.0*	*$1.5*	*$2.0*	*$2.5*	*$3.0*
EBIT	**($36.3)**	**($15.5)**	**($39.5)**	**($13.0)**	**$1.9**	**$14.8**	**$77.2**	**$119.0**	**$186.9**	**$205.8**	**$239.1**	**$261.0**
EBITDA margin	-	-	*-790.0%*	*-52.0%*	*2.9%*	*18.4%*	*47.3%*	*53.3%*	*60.6%*	*61.1%*	*62.7%*	*63.5%*
Cash Taxes	$0	$0	$0	$0	$0.0	($3.0)	($24.7)	($38.1)	($59.8)	($65.8)	($76.5)	($83.5)
Tax Rate	*0%*	*0%*	*0%*	*0%*	*0%*	*20.0%*	*32.0%*	*32.0%*	*32.0%*	*32.0%*	*32.0%*	*32.0%*
Balance Sheet												
Capital Expenditures	$0.5	$0.5	$1.0	$2.5	$3.0	$2.0	$1.0	$0.5	$0.5	$0.5	$0.5	$0.5
Working Capital	$1.0	$1.0	$1.0	$1.0	$1.0	$1.5	$2.0	$2.5	$3.0	$3.5	$4.0	$4.5
Non-Cash Adjustments	($1.0)	($1.0)	($1.0)	($1.0)	($1.0)	($1.0)	($1.0)	($1.0)	($1.0)	($1.0)	($1.0)	($1.0)
Capital Adjustments	**$0.5**	**$0.5**	**$1.0**	**$2.5**	**$3.0**	**$2.5**	**$2.0**	**$2.0**	**$2.5**	**$3.0**	**$3.5**	**$4.0**
Discounted Cash Flow												
Cash Income	($36.3)	($15.5)	($39.5)	($13.0)	$1.9	$11.8	$52.5	$80.9	$127.1	$139.9	$162.6	$177.5
Depreciation and amortization	$0.5	$0.5	$0.5	$0.5	$0.5	$0.5	$0.5	$1.0	$1.5	$2.0	$2.5	$3.0
Net Cash Changes	($0.5)	($0.5)	($1.0)	($2.5)	($3.0)	($2.5)	($2.0)	($2.0)	($2.5)	($3.0)	($3.5)	($4.0)
Post-Tax Operating Cash Flow	**($36.3)**	**($15.5)**	**($40.0)**	**($15.0)**	**($0.6)**	**$9.8**	**$51.0**	**$79.9**	**$126.1**	**$138.9**	**$161.6**	**$176.5**
Dividends / Payments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Free Cash Flow	**($36.3)**	**($15.5)**	**($40.0)**	**($15.0)**	**($0.6)**	**$9.8**	**$51.0**	**$79.9**	**$126.1**	**$138.9**	**$161.6**	**$176.5**

Assumptions	
Beta:	1.85
Equity Risk Premium:	8%
Risk Free Rate:	3%
Firm Risk Premium:	85%
Discount Rate:	**18%**

Valuation	
10-Year Model:	$123.7
Terminal Growth:	3%
Terminal Value:	$202.7
Net Cash - LT Debt:	$60.4
Firm Value:	**$386.8**

Price Target	
Basic Outstanding:	28.5
Warrants / Options:	4.1
Dilution:	2.5
Adjusted Fully Diluted:	35.2
Target Price:	**$10.99**

Source: Zacks Investment Research, Inc. Jason Napodano, CFA

PROJECTED FINANCIALS


Trius Therapeutics, Inc.
Income Statement

	2009 A	2010 A	Q1 A	Q2 A	Q3 A	Q4 E	2011 E	2012 E	2013 E	2014 E
Torezolid (N.A. Sales)	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-	-	-	-
Torezolid (EU Sales)	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-	-	-	-
Torezolid (Asia/EM Sales)	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
YOY Growth	-	-	-	-	-	-	-	-	-	-
Total Torezolid Revs	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**	**$0**
YOY Growth	-	-	-	-	-	-	-	-	-	-
Contracts & Collaborations	**$5.0**	**$8.0**	**$2.7**	**$2.9**	**$30.4**	**$5.5**	**$41.5**	**$25.0**	**$25.0**	**$20.0**
YOY Growth	-	-	-	-	-	-	*100.0%*	*-39.8%*	*0.0%*	*-20.0%*
Total Revenues	**$5.0**	**$8.0**	**$2.7**	**$2.9**	**$30.4**	**$5.5**	**$41.5**	**$25.0**	**$25.0**	**$20.0**
YOY Growth	-	*60.1%*	-	-	-	-	*100.0%*	*-39.8%*	*0.0%*	*-20.0%*
CoGS	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Product Gross Margin	*0%*	*0.0%*	-	-	-	-	*0.0%*	*0%*	*0%*	*0%*
R&D	$23.0	$23.3	$10.4	$10.4	$14.9	$13.5	$49.2	$40.0	$30.0	$30.0
% R&D	-	-	-	-	-	-	-	*160.0%*	*120.0%*	*150.0%*
SG&A	$4.1	$5.4	$2.3	$2.5	$3.7	$3.0	$11.6	$12.5	$14.0	$15.0
% SG&A	-	-	-	-	-	-	*27.8%*	*50.0%*	*56.0%*	*75.0%*
Operating Income	($22.2)	($20.7)	($10.1)	($10.0)	$11.8	($11.0)	($19.3)	($27.5)	($19.0)	($25.0)
Operating Margin	*0%*	*0.0%*	-	-	-	-	*-46.4%*	*-110.0%*	*-76.0%*	*-125.0%*
Interest & Other Income	($0.5)	($3.2)	$0.0	$0.0	$2.5	($0.1)	$2.4	($0.5)	($0.4)	($0.2)
Pre-Tax Income	($22.7)	($23.9)	($10.1)	($10.0)	$14.3	($11.1)	($16.8)	($28.0)	($19.4)	($25.2)
Taxes & Other	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Tax Rate	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*	*0%*
Net Income	($22.7)	($23.9)	($10.1)	($10.0)	$14.3	($11.1)	($16.9)	($28.0)	($19.4)	($25.2)
Net Margin	*0%*	*0.0%*	-	-	-	-	*-40.6%*	*-112.0%*	*-77.6%*	*-126.0%*
Reported EPS	**($31.09)**	**($2.36)**	**($0.43)**	**($0.40)**	**$0.49**	**($0.37)**	**($0.62)**	**($0.90)**	**($0.61)**	**($0.76)**
YOY Growth	-	*-92.4%*	-	-	-	-	*-73.7%*	*45.1%*	*-32.9%*	*26.0%*
Basic Shares Outstanding	0.7	10.1	23.6	25.3	29.5	30.0	27.1	31.0	32.0	33.0

Source: Zacks Investment Research, Inc. *Jason Napodano, CFA*

© Copyright 2011, Zacks Investment Research. All Rights Reserved.

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

The following disclosures relate to relationships between Zacks Investment Research ("ZIR") and Zacks Small-Cap Research ("Zacks SCR") and the issuers covered by the Zacks SCR analysts in the Small-Cap Universe.

ZIR or Zacks SCR Analysts do not hold or trade securities in the issuers which they cover. Each analyst has full discretion on the rating and price target based on their own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for non-investment banking services. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or blog.

ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Zacks SCR has never received compensation for investment banking services on the small-cap universe. Zacks SCR does not expect received compensation for investment banking services on the small-cap universe. Zacks SCR has received compensation for non-investment banking services on the small-cap universe, and expects to receive additional compensation for non-investment banking services on the small-cap universe, paid by issuers of securities covered by Zacks SCR. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, investment research, and investment management.

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change. Reports are not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. Zacks SCR uses the following rating system for the securities it covers. Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters. Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters. Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters.

The current distribution of Zacks Ratings is as follows on the 1046 companies covered: Buy/Outperform- 16.3%, Hold/Neutral- 75.3%, Sell/Underperform – 6.5%. Data is as of midnight on the business day immediately prior to this publication.

© Copyright 2011, Zacks Investment Research. All Rights Reserved.